Health Technology

Health Village Imaging, LLC Selects Healthcare Administrative Partners as Comprehensive Revenue Cycle Management Services Provider

Retrieved on: 
Tuesday, April 9, 2024
Health, Technology, Photography, Health Technology, Practice Management, Radiology, Partner, MRI, Practice management, Partnership, Patient, HVI, HAP, Property management

Healthcare Administrative Partners (HAP), a leading provider of outsourced billing, coding, and practice management solutions for radiology practices, today announces the addition of Health Village Imaging , LLC (HVI) to its roster of radiology revenue cycle management clients.

Key Points: 
  • Healthcare Administrative Partners (HAP), a leading provider of outsourced billing, coding, and practice management solutions for radiology practices, today announces the addition of Health Village Imaging , LLC (HVI) to its roster of radiology revenue cycle management clients.
  • Health Village Imaging is a full-service imaging center offering medical imaging services across central and southern New Jersey.
  • Under the terms of the agreement, HAP will perform all core revenue cycle services on behalf of Health Village Imaging including billing, coding, carrier credentialing, business intelligence, and MIPS Measure Assurance Services.
  • We are happy to expand upon our long-term relationship with Coastal Imaging by servicing Health Village Imaging’s revenue cycle management needs.”

SimBioSys Launches TumorSight Plan, A Pioneering Clinical Decision Support for Early-Stage Breast Cancer

Retrieved on: 
Tuesday, April 9, 2024
Technology, Biotechnology, Health, Consumer, Other Health, Radiology, Surgery, Artificial Intelligence, Oncology, Medical Devices, Software, General Health, Health Technology, Women, Breast cancer, MRI, Breast Cancer Care, Mastectomy, Science, Patient, Artificial intelligence, 3D, Cancer, Surgeon, Woman, Risk assessment, CMO, Simbiosys, FDA, Medicine, Medical imaging

Now, with TumorSight Plan, surgeons are empowered with visualization, data-driven insights, and best-practices to help support more effective provider-patient interactions and individualize treatment planning to right-size care.

Key Points: 
  • Now, with TumorSight Plan, surgeons are empowered with visualization, data-driven insights, and best-practices to help support more effective provider-patient interactions and individualize treatment planning to right-size care.
  • TumorSight Plan is powered by the FDA-cleared TumorSight Viz , an innovative 3D visualization solution to support the rapidly increasing use of MRI imaging in Breast Cancer.
  • SimBioSys’ TumorSight suite is a huge breakthrough in our capacity to utilize AI to calibrate a balance between decision standardization and individualized medicine.
  • TumorSight Plan gives the breast cancer surgeon a platform and opportunity to enable more analytical patient-centric decision making which should lead to higher percentage of women undergoing breast conservation surgery.”

IGC Pharma Adds Advisor in Artificial Intelligence

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, Technology, Health, Pharmaceutical, Health Technology, Other Science, Other Technology, Research, Artificial Intelligence, Science, Clinical Trials, Diagnosis, Agitation, Biomedicine, Mathematics, Universidad, Algorithm, Biomedical engineering, Paris Dauphine University, Risk, Patient, Artificial intelligence, AI, University, Deep learning, Universidad de los Andes, Computer vision, IGC, GxP, Dementia, Medical device

IGC Pharma, Inc. ("IGC Pharma," "IGC" or the "Company") (NYSE American: IGC) today announces the addition of Pablo Arbelaez, Ph.D., an expert in artificial intelligence (“AI”) and one of the world's top researchers.

Key Points: 
  • IGC Pharma, Inc. ("IGC Pharma," "IGC" or the "Company") (NYSE American: IGC) today announces the addition of Pablo Arbelaez, Ph.D., an expert in artificial intelligence (“AI”) and one of the world's top researchers.
  • This will help IGC Pharma identify individuals who are most likely to respond to treatment and accelerate the delivery of treatments to patients.
  • Pablo Arbeláez is a distinguished researcher with over 20 years of experience in Computer Vision and Artificial Intelligence.
  • Ram Mukunda, CEO of IGC Pharma, stated, "We welcome Dr. Pablo Arbelaez to our team of Senior Advisors.

HealthLock Bolsters Leadership Team with New Chief Revenue Officer, Chief Growth Officer to Meet Exponential Demand, Shape Future of Customer Experience

Retrieved on: 
Tuesday, April 9, 2024
Software, Payments, Health, Data Management, Health Technology, Technology, Health Insurance, Security, Avast, Philosophy, SVP, LifeLock, CGO, AVG, Yahoo!, Pinnacle Financial Partners, Gen, Engineering, Management

HealthLock , a leading medical fraud and overbilling protection solution, today announced its appointment of two seasoned executives to its leadership team: Adam Hewitt as Chief Revenue Officer (CRO) and David Putnam as Chief Growth Officer (CGO).

Key Points: 
  • HealthLock , a leading medical fraud and overbilling protection solution, today announced its appointment of two seasoned executives to its leadership team: Adam Hewitt as Chief Revenue Officer (CRO) and David Putnam as Chief Growth Officer (CGO).
  • Both leaders will usher in initiatives to increase awareness of HealthLock and cultivate the customer experience to meet the needs of consumers in today’s complex healthcare landscape.
  • As CRO, Hewitt brings specialty knowledge in the benefits administration space complemented by deep roots in private wealth and commercial banking.
  • “We couldn’t have found a better match for our leadership team and the future of our business,” said HealthLock CEO Scott Speranza.

Sanguine Biosciences Affirms Superior Quality of its Biospecimen Services Using VERIF.i®, Scientist.com’s Supplier Pre-assessment Program

Retrieved on: 
Tuesday, April 9, 2024
Technology, Biotechnology, Health, Other Health, Pharmaceutical, Oncology, Other Science, Research, Software, Genetics, Health Technology, Science, Data Management, Clinical Trials, Medicine, SVP, Collection, Category, Sanguine, Drug discovery

VERIF.i helps Scientist.com marketplace suppliers demonstrate internal processes and adherence to best practices to both existing and potential new clients.

Key Points: 
  • VERIF.i helps Scientist.com marketplace suppliers demonstrate internal processes and adherence to best practices to both existing and potential new clients.
  • “Through direct-to-donor engagement, Sanguine continues to amass one of the industry’s largest collections of ethically procured collections that includes extensive data about the biospecimens,” stated Sanguine CEO Brian Neman.
  • Their research products and services facilitate advanced therapy development programs from discovery to manufacturing.
  • “VERIF.i was developed to create a standardized process that helps researchers and sample providers ensure that the samples used in research meet their expected quality and ethical standards.”
    For more information on VERIF.i, visit https://www.scientist.com/verifi/

NanoVibronix Issues Letter to Stockholders

Retrieved on: 
Tuesday, April 9, 2024
Medical Devices, Health, Health Technology, Research, Science, Biotechnology, National Health Service, Growth, Partnership, COVID-19, Patient, SAW, Gold, NHS, University, University of Michigan, Quality of life, Insurance, GSA, Urinary tract infection, Pain, Medicare, FDA, CMS, Engineering, Food, Pharmaceutical industry

We are focused on several areas that we believe will have a substantial impact on our growth and product adoption.

Key Points: 
  • We are focused on several areas that we believe will have a substantial impact on our growth and product adoption.
  • A driving factor in our increased revenues was increased sales to customers using the Veterans’ Health System and worker’s compensation plans.
  • On our balance sheet for the period ended December 31, 2023, we had $3.3 million of cash and inventory of $2.7 million.
  • CMS invited NanoVibronix to a public meeting to present its findings and to answer CMS’s questions, which was held June 1, 2023.

Exponential Health Partners with Cardio Diagnostics to Elevate Cardiovascular Disease Prevention in Michigan

Retrieved on: 
Tuesday, April 9, 2024
Cardiology, Biotechnology, Technology, Health, General Health, Pharmaceutical, Health Technology, Other Technology, Medical Devices, Artificial Intelligence, Genetics, Diagnosis, Exponential, Cardio, Genomics, Cardiovascular disease, Growth, Entrepreneurship, Partnership, Risk, Patient, Artificial intelligence, Splenic infarction, Death, CHD, Medicine, Concierge medicine, Epigenomics, Moyamoya disease, USD, Medical device

As a result, Exponential Health is expanding access to a new chapter in the proactive management of heart disease.

Key Points: 
  • As a result, Exponential Health is expanding access to a new chapter in the proactive management of heart disease.
  • Concierge practices such as Exponential Health are leading the way in adopting epigenetic cardiovascular solutions.
  • "We are thrilled to partner with Dr. Baer and Exponential Health," said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics.
  • Integrating Cardio Diagnostics' advanced tests into Exponential Health's offerings is a proactive step toward mitigating this global health challenge.

Cariloop Secures $20 Million in Series C Funding to Accelerate Growth and Expand Caregiver Support Solutions

Retrieved on: 
Tuesday, April 9, 2024
Software, Managed Care, General Health, Professional Services, Family, Data Management, Consumer, Technology, Health Technology, Human Resources, Consulting, Health, ASPCA, Organization, KPMG, Growth, Entrepreneurship, Caregiver, Procter & Gamble, American Cancer Society, NPS, ABS Capital Partners, CAE, Investment, ABS, Traction, Workforce, Series, Insperity

Cariloop, the leading comprehensive caregiver support platform, today announced the successful closure of its Series C funding round, raising $20 million.

Key Points: 
  • Cariloop, the leading comprehensive caregiver support platform, today announced the successful closure of its Series C funding round, raising $20 million.
  • “The service we provide gives companies a way to support their working caregivers and drive employee wellbeing, productivity and retention.
  • As part of the Series C financing, Krusius will join Cariloop’s Board of Directors and Cal Wheaton, Partner at ABS Capital, will join as a Board Observer.
  • Steven Theesfeld, Cariloop’s Co-Founder, and Colin Patrick, Patterson Thoma Family Office’s Chief Investment Officer, will step down from the Board.

GE HealthCare to Announce First Quarter 2024 Results on April 30, 2024

Retrieved on: 
Tuesday, April 9, 2024
Data Analytics, Health, Professional Services, Pharmaceutical, Health Technology, Webcast, GE HealthCare

GE HealthCare (Nasdaq: GEHC), a leader in precision care innovation, will announce its first quarter 2024 financial results before the market opens on Tuesday, April 30, 2024.

Key Points: 
  • GE HealthCare (Nasdaq: GEHC), a leader in precision care innovation, will announce its first quarter 2024 financial results before the market opens on Tuesday, April 30, 2024.
  • The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events .
  • The earnings release, accompanying financial information, and webcast replay will also all be posted at the same link on the GE HealthCare Investor Relations website.

Media Advisory: DoseMe Bioinformatician and Chief Science and Strategy Officer Co-Author Abstract Big Data Bayesian Truths to Be Covered in Oral Presentation at the 24th ECCMID Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, Pharmaceutical, Health, Infectious Diseases, Hospitals, Health Technology, Genetics, Clinical Trials, Congress, Midwestern University, BCPS, Doctor of Pharmacy, Professor, AUC, Patient, Big data, Vancomycin, Safety, ESCMID, ECCMID, European, Infection, Pharmaceutical industry

ECCMID is the annual meeting of ESCMID, the European Society of Clinical Microbiology and Infectious Diseases, a registered non-profit organization in Basel, Switzerland.

Key Points: 
  • ECCMID is the annual meeting of ESCMID, the European Society of Clinical Microbiology and Infectious Diseases, a registered non-profit organization in Basel, Switzerland.
  • Abstract co-authored Dr. Sharmeen Roy, PharmD, BCPS , Chief Strategy and Science Officer and Paul Sabourenkov , Lead Bioinformatician at DoseMe.
  • What: Abstract 05305, Big Data Bayesian Truths: no vancomycin trough concentration target is sufficiently precise for safety or efficacy.
  • Details: Title: Big data Bayesian truths: no vancomycin trough concentration target is sufficiently precise for safety or efficacy.